• 1
    Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347354.
  • 2
    Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS Heath-cote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen–positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 199: 312323.
  • 3
    Korenman J, Baker B, Waggoner J, Everhart JE, DiBisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629634.
  • 4
    Carreño V, Castillo I, Molina J, Porres JC, Bartolomé J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15: 102106.
  • 5
    Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 18331838.
  • 6
    Niederau C, Heintges T, Lange S, Goldmann, G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14221427.
  • 7
    Lok ASF, Wu PC, Lai CL, Lan JYN, Leung EKY, Wong LSK, Ma OCK, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 20912097.
  • 8
    Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908916.
  • 9
    Hoofnagle JH, DiBisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 11161121.
  • 10
    Benhamou Y, Katlama CH, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, et al. Effects of lamivudine on replication of hepatitis B virus in infected men. Ann Intern Med 1996; 129: 17051712.
  • 11
    Tyrrell DLJ, Fischer K, Savani K, Tan W, Jewell L. Treatment of chimpanzees and ducks with lamivudine 2′3′ dideoxy 3′thiacytidine results in a rapid suppression of hepadnaviral DNA in sera [Abstract]. Clin Invest Med 1993; 16 (suppl 4): B77.
  • 12
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 84958499.
  • 13
    Severini A, Liu XY, Wilson JS, Tyrrell LJ. Mechanism of inhibition of duck hepatitis B virus polymerase by 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995; 39: 14301435.
  • 14
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 16571661.
  • 15
    Lai CL, Ching CK, Tung ANM, Li E, Young J, Hill A, Wong BCY, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25: 241244.
  • 16
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711713.
  • 17
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA–dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714717.
  • 18
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bun-zendahl H, Condreay L, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 2022.
  • 19
    Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, Tipples G, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 14561462.
  • 20
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 12121215.
  • 21
    Dienstag JL, Schiff ER, Mitchell M, Gitlin N, Lissoos T, Condreay L, Garrett L, et al. Extended lamivudine retreatment for chronic hepatitis B [Abstract]. Hepatology 1996; 24: 188A.
  • 22
    Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine in vitro. Antimicrob Agents Chemother 1996; 40: 19571960.
  • 23
    Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, et al. Development of HIV-1 resistance to 2′3′-dideoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9: 351357.
  • 24
    Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90: 56535656.
  • 25
    Cirelli R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996; 29: 141151.
  • 26
    Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996; 40: 12821284.
  • 27
    Shaw T, Amor G, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994; 38: 719723.
  • 28
    Lin E, Luscombe C, Wang YY, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996; 40: 413418.
  • 29
    Main J, Brown JL, Karayiannins P, Georgiou P, Howells C, Balassini R, Crossey M, et al. A double-blind, placebo-controlled study to asssess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3: 211215.
  • 30
    Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study [Abstract]. Hepatology 1996; 24: 188A.
  • 31
    Prieto, M, Cordoba, J, Berenguer, M, Rayon M, Carrasco D, Olaso V, Mir J, et al. Famciclovir treatment of hepatitis B virus (HBV) infection after liver transplantation: a pilot study [Abstract]. Hepatology 1996; 24: 419A.
  • 32
    Kruger M, Tillmann HL, Trautwein C, Oldhafer K, Boker KHW, Pichl-mayr R, Manns MP, et al. Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation: a pilot study [Abstract]. Hepatology 1995; 22: 219A.
  • 33
    Rabinovitz M, Dodson F, Rakela J. Famciclovir for recurrent hepatitis B (HBV) infection after liver transplantation [Abstract]. Hepatology 1996; 24: 282A.
  • 34
    Aye TT, Bartholomeusz Al, Shaw T, Breschkin AM, Gronen L, Bowden DS, McMillan JS, et al. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation [Abstract]. Hepatology 1996; 24: 285A.
  • 35
    Corey L, Holmes KK. Therapy for human immunodeficiency virus infection–what have we learned? N Engl J Med 1996; 335: 11421144.
  • 36
    de Jong MC, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA, Richman DD. Consensus symposium on combined antiviral therapy. Antiviral Res 1995; 29: 529.
  • 37
    Larden BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT–3TC combination therapy. Science 1995; 269: 696699.
  • 38
    Colledge D, Locarini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216225.
  • 39
    Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996; 24: 17.
  • 40
    Zoulim F, Dannaoui E, Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription. Abstracts of the 35th Interscience conference on antimicrobial agents and chemotherapy [Abstract]. 1995; 182.
  • 41
    Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1995; 29: 4951.
  • 42
    Marines G, Naoumov NV, Williams R . Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996; 24: 991995.